Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon
Free accessResearch articleFirst published online January, 2013
Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon
Although treatment adherence is a major challenge in sub-Saharan Africa, it is still unknown which longitudinal patterns of adherence are the most detrimental to long-term virological response to non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens. This analysis aimed to study the influence of different time patterns of adherence on virological failure after 24 months of treatment in Cameroon.
Methods
Antiretroviral therapy (ART) adherence data were collected using face-to-face questionnaires administered at months 1, 3, 6, 12, 18 and 24. Virological failure was defined as viral load >40 copies/ml at month 18 and/or 24. Two combined indicators of early adherence (months 1, 3 and 6) and adherence during the maintenance phase (months 12, 18 and 24) were designed to classify patients as always adherent during the early or maintenance phase, non-adherent at least once and having interrupted ART for >2 days at least once at any visit during either of these two phases.
Results
Virological failure occurred in 107 (42%) of the 254 patients included in the analysis. In the early and maintenance phases, 84% and 76%, respectively, were always adherent, 5% and 5% were non-adherent and 11% and 20% experienced ≥1 treatment interruption. Early non-adherence was independently associated with virological failure (adjusted OR 7.2 [95% CI 1.5, 34.6]), while only treatment interruptions had a significant impact on virological failure during the maintenance phase (adjusted OR 2.1 [95% CI 1.1, 4.4]).
Conclusions
ART NNRTI-regimens used in sub-Saharan Africa seem to ‘forgive’ deviations from good adherence during the maintenance phase. Optimizing adherence in the early months of treatment remains crucial, especially in a setting of poor health care infrastructure and resources.
References
1.
BakerJ.V., PengG., RapkinJ.CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS2008; 22: 841–848.
2.
HullM.W., MontanerJ.Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep2011; 8: 85–93.
3.
Eyer-SilvaW.A., Couto-FernandezJ.C., Silva-de-JesusC., MorgadoM.G.Prevalence of HIV type 1 drug resistance mutations in treatment-naive and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities. Mem Inst Oswaldo Cruz2008; 103: 143–149.
4.
HaubrichR.H., LittleS.J., CurrierJ.S.The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS1999; 13: 1099–1107.
5.
PressN., TyndallM.W., WoodE., HoggR.S., MontanerJ.S.Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr2002; 31Suppl 3: S112–S117.
6.
El-KhatibZ., EkstromA.M., CoovadiaA.Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa – a prospective cohort study. BMC Public Health2011; 11: 88.
7.
ChiB.H., CantrellR.A., ZuluI.Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol2009; 38: 746–756.
8.
CarrieriM.P., RaffF., LewdenC.Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther2003; 8: 585–594.
9.
BraitsteinP., BrinkhofM.W., DabisF.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet2006; 367: 817–824.
10.
LaurentC., KouanfackC., Laborde-BalenG.Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis2011; 11: 825–833.
11.
BoyerS., EbokoF., CamaraM.Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS2010; 24Suppl 1: S5–S15.
12.
World Health Organization.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 Revision. Geneva: World Health Organization2006.
13.
CarrieriP., CailletonV., Le MoingV.The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr2001; 28: 232–239.
14.
OyugiJ.H., Byakika-TusiimeJ., RaglandK.Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS2007; 21: 965–971.
15.
HosmerD.W., LemeshowS.Applied Logistic Regression.2nd ed. New York: Wiley; 2000.
16.
HeckmanJ.The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Annals of Economic and Social Measurement1976; 5: 475–492.
17.
LittleR.J., RubinD.B.Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health2000; 21: 121–145.
18.
CarrieriM.P., LeportC., ProtopopescuC.Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr2006; 41: 477–485.
19.
BangsbergD.R.Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis2006; 43: 939–941.
20.
FordN., DarderM., SpelmanT.Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS ONE2010; 5: e10460.
21.
FieldingK.L., CharalambousS., StensonA.L.Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis2008; 8: 93.
22.
ShuterJ.Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother2008; 61: 769–773.
23.
LimaV.D., BangsbergD.R., HarriganP.R.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr2010; 55: 460–465.
24.
BangsbergD.R., AcostaE.P., GuptaR.Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS2006; 20: 223–231.
25.
GardnerE.M., HullsiekK.H., TelzakE.E.Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS2010; 24: 395–403.
26.
World Health Organization.Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach.Geneva: World Health Organization2003.
27.
HodderS., ArastehK., De WetJ.Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med2012; 13: 406–415.
28.
MaveV., GahuniaM., FrontiniM., ClarkR., MushattD.Gender differences in HIV drug resistance mutations and virological outcome. J Womens Health (Larchmt)2011; 20: 117–122.
29.
MutevedziP.C., LessellsR.J., RodgerA.J., NewellM.L.Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS ONE2011; 6: e21795.
30.
WoutersE., Van DammeW., Van LoonF., van RensburgD., MeulemansH.Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome. Soc Sci Med2009; 69: 1177–1185.
31.
ZachariahR., TeckR., BuhendwaL.How can the community contribute in the fight against HIV/AIDS and tuberculosis? An example from a rural district in Malawi. Trans R Soc Trop Med Hyg2006; 100: 167–175.
32.
GusdalA.K., ObuaC., AndualemT.Peer counselors’ role in supporting patients’ adherence to ART in Ethiopia and Uganda. AIDS Care2011; 23: 657–662.
33.
WoutersE., van LoonF., van RensburgD., MeulemansH.Community support and disclosure of HIV serostatus to family members by public-sector antiretroviral treatment patients in the Free State Province of South Africa. AIDS Patient Care STDS2009; 23: 357–364.
34.
MaskewM., MacPhailP., MenezesC., RubelD.Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J2007; 97: 853–857.
35.
MillerC.M., KetlhapileM., Rybasack-SmithH., RosenS.Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health2010; 15Suppl 1: 48–54.
36.
BoyerS., ClercI., BononoC.R.Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc Sci Med2011; 72: 1383–1392.
ChalkerJ.C., AndualemT., GitauL.N.Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res2010; 10: 43.
39.
TurnerB.J.Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis2002; 185Suppl 2: S143–S151.
